On Tuesday, in the course of current trade, Shares of SeaDrill Limited (NYSE:SDRL), surged 4.92%, and is now trading at $14.51.
Seadrill Limited, is planned to release its first quarter 2015 results on Thursday May 28th, 2015.
In connection with the earnings release, a conference call/webcast will be held at 12:00 p.m. EDT / 5:00 p.m. BST on Thursday May 28th, 2015.
Seadrill Limited, an offshore drilling contractor, provides offshore drilling services to the oil and gas industry worldwide. The company operates through Floaters and Jack-up Rigs segments.
During an Afternoon trade, Shares of United Technologies Corporation (NYSE:UTX), dipped -0.44%, and is now trading at $117.18.
Kidde Fire Safety, the company that millions of U.S. consumers rely on for fire safety products, now offers the Remote Lync Monitor nationwide exclusively at The Home Depot. The listening device alerts consumers when they are away from home to a potential fire or carbon monoxide (CO) risk via a free iOS- or Android-compatible app, text, or email. Kidde, a leading manufacturer of residential fire safety products, is a part of UTC Building & Industrial Systems, a unit of United Technologies Corp. (UTX).
Designed as a user-friendly way to support a “connected home,” the Remote Lync Monitor does not require additional products, hubs or monthly fees to function. It simply plugs into a single outlet, listens for the unique beeping pattern of existing smoke or CO alarms, and uses a home’s existing wireless Internet connection to contact homeowners if an alarm sounds.
United Technologies Corporation provides technology products and services to building systems and aerospace industries worldwide. Its Otis segment designs, manufactures, sells, and installs passenger and freight elevators, escalators, and moving walkways; modernization products to upgrade elevators and escalators; and maintenance and repair services.
Shares of AngloGold Ashanti Ltd. (NYSE:AU), during its Tuesday’s current trading session gained 0.27%, and is now trading at $11.17.
AngloGold Ashanti, posted a first-quarter operational performance ahead of market guidance, with a 7% year-on-year improvement in all-in sustaining costs (AISC) due mainly to a strong result from its international mines. The company maintained its full-year guidance for production, costs and capital expenditure.
Production was 969,000oz at total cash cost of $744/oz in the three months through March 31, 2015, down from 1.055Moz at $770/oz in the first quarter of last year. Production was affected by a slow start in South Africa after the Christmas break, the sale of the Navachab mine last year in addition to the transition of Obuasi to limited operations phase in December. The result contrast with guidance of 900,000oz to 940,000oz at $830/oz to $860/oz/oz. AISC improved from $993/oz to $926/oz, while all-in-costs reduced by 8% from $1,114/oz to $1,026/oz over the same period.
AngloGold Ashanti Limited operates as a gold mining and exploration company. It also produces silver, uranium oxide, copper, molybdenum, and sulphur. The company has 20 operations and exploration projects in South Africa, Continental Africa, Australasia, and the Americas. AngloGold Ashanti Limited was founded in 1944 and is headquartered in Johannesburg, South Africa.
Finally, Eli Lilly and Company (NYSE:LLY), lost -1.35% Tuesday.
Eli Lilly and Company, and BioNTech AG declared they have reached a research partnership to discover novel cancer immunotherapies. The companies will seek to use the power of the body’s own immune system to attack cancer cells and create possible new treatment options for cancer patients.
Leveraging the scientific expertise between the two organizations, Lilly and BioNTech will collaborate to identify and validate novel tumor targets and their corresponding T cell receptors (TCRs) in one or more types of cancer. These tumor targets and TCRs may then be engineered and developed into potent and selective cancer therapies.
Under the terms of the agreement, BioNTech will receive a $30 million signing fee. For each potential medicine, BioNTech could receive over $300 million in development, regulatory and commercial milestones. If successfully commercialized, BioNTech would also be eligible for tiered royalty payments up to double-digits. In addition, subject to the terms of the agreement, Lilly will make a $30 million equity investment in BioNTech’s partner, Cell & Gene Therapies GmbH, which specializes in the research and development of TCR and chimeric antigen receptor immunotherapeutics. Further financial terms were not revealed.
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
